| Theme | Perspective for Chemotherapy in Gastrointestinal Malignancy Based on Current Evidence | |
|---|---|---|
| Title | New Developments of Perioperative Chemotherapy for Colorectal Cancer | |
| Publish Date | 2013/03 | |
| Author | Keisuke Kirita | Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East |
| Author | Hideaki Bando | Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East |
| Author | Takayuki Yoshino | Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East |
| [ Summary ] | Patients with resectable colon cancer may develop a resistance to adjuvant treatment. This is true of patients considered to be at stage III levels or even those considered to be high risk stage II. The effectiveness of FOLFOX and XELOX as adjuvant chemotherapy agents has been proven. Combination therapy with molecular targeted agents provides no better levels of treatment than therapy without molecular targeted agents. There are ongoing discussions concerning the optimal duration of these therapies and risk of recurrence. Genetic profiling is one method these treatments may be refined and implemented. FOLFOX is considered to be an effective neoadjuvant or adjuvant therapy for resectable colon cancer associated with liver metastases. On the other hand, cases which are considered to be unresectable, may receive conversion therapy with the aim of achieving radical cures through high reduction effects. In Western countries, local progression of rectal cancer is treated with neoadjuvant chemoradiotherapy combined with 5-FU. The addition of oxaliplatin to those therapies is also being investigated. |
|